Perceptive Advisors LLC Cogent Biosciences, Inc. Transaction History

Perceptive Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.38 - $9.02 $1.05 Million - $2.16 Million	-239,625 Reduced 21.34%	883,333 $5.94 Million
Q4 2023 Feb 14, 2024	SELL	$4.06 - $10.08 $4.82 Million - $12 Million	-1,186,512 Reduced 51.38%	1,122,958 $6.6 Million
Q3 2023 Nov 14, 2023	SELL	$9.69 - $13.34 $3.39 Million - $4.67 Million	-350,000 Reduced 13.16%	2,309,470 $22.5 Million
Q2 2023 Aug 14, 2023	BUY	$9.85 - $13.24 $3.71 Million - $4.99 Million	377,146 Added 16.52%	2,659,470 $31.5 Million
Q1 2023 May 15, 2023	SELL	$10.04 - $15.5 $9.29 Million - $14.3 Million	-925,117 Reduced 28.84%	2,282,324 $24.6 Million
Q3 2022 Nov 14, 2022	BUY	$9.39 - $16.99 $1.11 Million - $2.01 Million	118,469 Added 3.84%	3,207,441 $47.9 Million
Q2 2022 Aug 15, 2022	SELL	$3.92 - $9.73 $391,129 - $970,839	-99,778 Reduced 3.13%	3,088,972 $27.9 Million
Q4 2020 Feb 16, 2021	BUY	$9.04 - $13.01 $28.8 Million - $41.5 Million	3,188,750 New	3,188,750 $35.8 Million

159

114M

104K

163K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $717M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.